No Data
No Data
Express News | Shuanglu Pharmaceutical: The antiallergic drug desloratadine has submitted a marketing application and is about to be approved for marketing
Express News | Shuanglu Pharmaceutical: Net profit of 70.1346 million yuan in the first quarter, a year-on-year decrease of 65.27%
“Jia Ling Lose Weight” has been trending for 4 days in a row. Will the number one investment theme in the Year of the Dragon be a comeback of the diet pill concept?
Under the popularity of the topic, the market speculates: will diet pills become the first investment theme in the Year of the Dragon?
Shuanglu Pharmaceutical (002038.SZ): 2023 net profit pre-increased by 66%-100%
Gelonghui, January 26 | Shuanglu Pharmaceutical (002038.SZ) announced its 2023 annual results forecast. Net profit and profit attributable to shareholders of listed companies during the reporting period was about 39 million yuan to 47 million yuan, an increase of about 66%-100% over the same period of the previous year; net profit after deducting non-recurring profit and loss was about 20 million yuan to 250 million yuan, an increase of about 40%-75% over the same period last year; basic earnings per share were about 0.38 yuan/share - 0.46 yuan/share. During the reporting period, the company's net profit attributable to shareholders of listed companies increased significantly. The first is the company's non-recurring losses
Gene therapy may open a new chapter in the pharmaceutical field, and the industry has broad prospects for growth
① Gene therapy developer VoyagerTherapeutics has reached a strategic cooperation and licensing agreement with Novartis Pharmaceuticals subsidiaries to advance novel gene therapies for Huntington's disease and spinal muscular atrophy. ② The agency expects the global gene editing market to reach US$36.61 billion by 2030, with a compound annual growth rate of 22.3%.
A-share review: the three major indices fell slightly, and sectors such as diet pills, wind power equipment and auto parts fell
Greenway, December 7 | In US dollars, China's exports in November increased 0.5% year on year, exceeding expectations; the main A-share index opened low today and rebounded in the afternoon. At the close, the Shanghai Index fell 0.09% to 2,966 points, the Shenzhen Stock Exchange Index fell 0.14%, and the GEM Index fell 0.25%. Nearly 3,200 shares in the two markets fell, trading for 820.2 billion yuan throughout the day, and the net purchase of capital going north was 373 million yuan. On the market, the spatial computing sector rose sharply in the afternoon, and many stocks such as Guomai Culture rose and stopped; Google launched the artificial intelligence model Gemini, artificial intelligence concept stocks rose, AIGC led the way, and many stocks such as Netda Software rose and stopped
No Data